His primary areas of investigation include Internal medicine, Lupus erythematosus, Connective tissue disease, Immunology and Placebo. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery. Kenneth C. Kalunian combines subjects such as Severity of illness and Quality of life with his study of Connective tissue disease.
His studies in Immunology integrate themes in fields like Lupus nephritis, Haplotype and Clinical significance. He interconnects Anti-nuclear antibody, Systemic lupus, Recursive partitioning, Derivation and Comorbidity in the investigation of issues within Clinical significance. His study in Placebo is interdisciplinary in nature, drawing from both Adverse effect and Randomized controlled trial.
His main research concerns Internal medicine, Immunology, Lupus erythematosus, Systemic lupus erythematosus and Rheumatology. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Placebo and Surgery. As a member of one scientific family, Kenneth C. Kalunian mostly works in the field of Immunology, focusing on Lupus nephritis and, on occasion, Proteinuria and Renal biopsy.
His Lupus erythematosus study combines topics in areas such as Disease activity, Cohort study, Anti-nuclear antibody, Prospective cohort study and Severity of illness. His Systemic lupus erythematosus research is multidisciplinary, incorporating elements of Lupus anticoagulant and Hazard ratio. He has researched Rheumatology in several fields, including Osteoarthritis, Physical therapy, Quality of life and Arthroscopy.
The scientist’s investigation covers issues in Internal medicine, In patient, Rheumatology, Lupus erythematosus and Systemic lupus erythematosus. His Internal medicine research incorporates elements of Gastroenterology and Placebo. The concepts of his Placebo study are interwoven with issues in Anti-nuclear antibody and Corticosteroid.
The Rheumatology study combines topics in areas such as Renal function, Immunology, Arthroscopy, Disease and Frailty Index. As a part of the same scientific study, Kenneth C. Kalunian usually deals with the Lupus erythematosus, concentrating on Young adult and frequently concerns with Cohort study and Lupus vasculitis. The study incorporates disciplines such as Clinical trial, Complement system, Low Complement and Hazard ratio in addition to Systemic lupus erythematosus.
Internal medicine, Lupus erythematosus, Systemic lupus erythematosus, Young adult and Rheumatology are his primary areas of study. His Internal medicine study frequently involves adjacent topics like Placebo. His Placebo study incorporates themes from Gastroenterology, Corticosteroid and Clinical endpoint.
His Lupus erythematosus research includes themes of Anti-nuclear antibody, Autoantibody, Predictive value of tests and Low Complement. His Systemic lupus erythematosus research integrates issues from Polypharmacy and Prospective cohort study. His studies deal with areas such as Frailty Index and Hazard ratio as well as Rheumatology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon.
Arthritis & Rheumatism (2012)
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.
Dafna Gladman;Ellen Ginzler;Charles Goldsmith;Paul Fortin.
Arthritis & Rheumatism (1996)
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Michelle Petri;Mimi Y. Kim;Kenneth C. Kalunian;Jennifer Grossman.
The New England Journal of Medicine (2005)
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus.
Dafna D. Gladman;Murray B. Urowitz;Charles H. Goldsmith;Paul Fortin.
Arthritis & Rheumatism (1997)
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial
Jill P. Buyon;Michelle A. Petri;Mimi Y. Kim;Kenneth C. Kalunian.
Annals of Internal Medicine (2005)
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.
Gary S. Hoffman;Maria C. Cid;David B. Hellmann;Loic Guillevin.
Arthritis & Rheumatism (2002)
Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie;Munther Khamashta;Joan T. Merrill;Victoria P. Werth.
Arthritis & Rheumatism (2017)
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
Kenneth C. Kalunian;John C. Davis;Joan T. Merrill;Mark C. Totoritis.
Arthritis & Rheumatism (2002)
Proinflammatory high‐density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis
Maureen McMahon;Jennifer Grossman;John FitzGerald;Erika Dahlin-Lee.
Arthritis & Rheumatism (2006)
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
Maria Dall'Era;Eliza Chakravarty;Daniel Wallace;Mark Genovese.
Arthritis & Rheumatism (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: